1125 Reata FA
BioCentury & Getty Images

Product Development

Friedreich’s ataxia program hits FDA snag, denting Reata’s shares

Nov 25, 2020 | 9:16 PM GMT

FDA’s conclusion about data Reata added to a potentially registrational package for its Friedreich’s ataxia program sliced about $420

Read the full 419 word article

How to gain access

Continue reading with a
two-week free trial.